Cluster designation 5 staining of normal and non-lymphoid neoplastic skin *
dc.contributor.author | Bogner, Paul N. | en_US |
dc.contributor.author | Su, Lyndon D. | en_US |
dc.contributor.author | Fullen, Douglas R. | en_US |
dc.date.accessioned | 2010-06-01T18:35:09Z | |
dc.date.available | 2010-06-01T18:35:09Z | |
dc.date.issued | 2005-01 | en_US |
dc.identifier.citation | Bogner, Paul N.; Su, Lyndon D.; Fullen, Douglas R. (2005). "Cluster designation 5 staining of normal and non-lymphoid neoplastic skin * ." Journal of Cutaneous Pathology 32(1): 50-54. <http://hdl.handle.net/2027.42/71788> | en_US |
dc.identifier.issn | 0303-6987 | en_US |
dc.identifier.issn | 1600-0560 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/71788 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15660655&dopt=citation | en_US |
dc.description.abstract | Immunohistochemical staining for cluster designation 5 (CD5) has been found to label a variety of non-lymphoid tumors. Methods: A variety of eccrine, apocrine, follicular, epithelial, and pagetoid lesions were selected and stained with an anti-CD5 monoclonal antibody (Novocastra Labs, Newcastle upon Tyne, UK, clone 4C7) by immunohistochemistry. The intensity of positive cytoplasmic staining was graded semiquantitatively (1+ weak staining, 2+ strong staining). Additionally, the percentage of positive lesional cells was placed in one of four categories: >75%, 25–75%, 1–25%, and <1%. Results: Within normal skin, CD5 labeled lymphocytes, apocrine glands, deep dermal eccrine glands, and smooth muscle (weak). The majority of benign and malignant apocrine lesions demonstrated strong focal (36%, n = 11)-to-diffuse (64%, n = 16) staining. In contrast, labeling of benign eccrine tumors was more focal, tending to localize around ducts (79%, n = 19). Microcystic adnexal carcinoma demonstrated focal staining of deeper ductal structures (71%, n = 7), whereas desmoplastic trichoepithelioma and basal cell carcinoma showed only rare positive cells. All cases of mammary (n = 7) and extramammary (n = 8) Paget's disease labeled diffusely for CD5. Pagetoid Bowen's disease (n = 6), intraepidermal sebaceous carcinoma (n = 3), nor melanoma in situ (n = 6) showed any CD5 staining. Conclusions: Immunohistochemical staining for CD5 is extremely useful in the differential diagnosis of pagetoid epidermal lesions and will mark mammary and extramammary Paget's disease, but not pagetoid Bowen's disease, melanoma in situ , or sebaceous carcinoma. Bogner PN, Su LD, Fullen DR. Cluster designation 5 staining of normal and non-lymphoid neoplastic skin. | en_US |
dc.format.extent | 4321730 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Munksgaard International Publishers | en_US |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | Blackwell Munksgaard, 2005 | en_US |
dc.title | Cluster designation 5 staining of normal and non-lymphoid neoplastic skin * | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Dermatology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Dermatology, University of Michigan Medical Center, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Department of Pathology, and | en_US |
dc.identifier.pmid | 15660655 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/71788/1/j.0303-6987.2005.00253.x.pdf | |
dc.identifier.doi | 10.1111/j.0303-6987.2005.00253.x | en_US |
dc.identifier.source | Journal of Cutaneous Pathology | en_US |
dc.identifier.citedreference | Itakura K, Hutton JJ, Boyse EA, Old LJ. Linkage groups of the theta and Ly-A loci. Nat New Biol 1971; 230: 126. | en_US |
dc.identifier.citedreference | Morse HC. Genetic nomenclature for loci controlling surface antigens of mouse hemopoietic cells. J Immunol 1992; 149: 3129. | en_US |
dc.identifier.citedreference | Hishima T, Fukayama M, Fujisawa M, et al. CD5 expression in thymic carcinoma. Am J Pathol 1994; 145: 268. | en_US |
dc.identifier.citedreference | Berezowski K, Grimes MM, Gal A, et al. CD5 immunoreactivity of epithelial cells in thymic carcinoma and CASTLE using paraffin-embedded tissue. Am J Clin Pathol 1996; 106: 483. | en_US |
dc.identifier.citedreference | Kuo TT, Chan JK. Thymic carcinoma arising in thymomas is associated with alterations in immunohistochemical profile. Am J Surg Pathol 1998; 22: 1474. | en_US |
dc.identifier.citedreference | Dorfman DM, Shahsafaei A, Chan JK. Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity. Am J Surg Pathol 1997; 21: 936. | en_US |
dc.identifier.citedreference | Tateyama H, Eimoto T, Tada T, et al. Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma. Am J Clin Pathol 1999; 111: 235. | en_US |
dc.identifier.citedreference | Kornstein MJ, Rosai J. CD5 labeling of thymic carcinomas and other nonlymphoid neoplasms. Am J Clin Pathol 1998; 109: 722. | en_US |
dc.identifier.citedreference | Shousha S, Costello C, Luqmani YA, et al. CD5 positive breast carcinoma in a patient with untreated chronic lymphocytic leukaemia: molecular studies of chromosome 13q. J Clin Pathol 1998; 51: 862. | en_US |
dc.identifier.citedreference | Walsh R, Peston D, Shousha S. Comparison of immunoperoxidase staining of 3 different types of CD5 antibodies in a spectrum of breast lesions. Arch Pathol Lab Med 2001; 125: 781. | en_US |
dc.identifier.citedreference | Fung MA, Murphy MJ, Hoss DM, et al. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol 2002; 46: 325. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.